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Abstract
Background: Murine cytomegalovirus (MCMV) is closely related to human cytomegalovirus (HCMV) which is
responsible for a variety of diseases, including retinitis, in immunocompromised individuals. Small inhibitory RNA
molecules directed against essential viral regulatory genes may prove clinically useful.
Methods: Small hairpin RNAs (shRNAs) directed against the essential MCMV immediate early-3 gene (IE-3) were
designed and tested in vitro at m.o.i.’s of 2 and 0.2 to determine if virus replication could be inhibited.
Results: At m.o.i. = 2, a MCMV IE-3 specific shRNA specific for sequences at the beginning of exon 5 inhibited
virus replication with a maximum decrease in virus titer of approximately two logs at day 5 p.i. Surprisingly,
however, at m.o.i. = 0.2, the same shRNA enhanced virus replication. In the latter case, the main IE-3 product
observed in infected cells was not the expected 88 kd full length IE-3 protein observed at high m.o.i. but rather a
truncated 45 kd form of this protein. Rapid analysis of 5’ cDNA ends (5’ RACE) indicated that substantial differences
exist in the transcript profile produced by the IE-3 gene at low and high m.o.i. early after infection and that
multiple transcripts are produced under both conditions. One such transcript, which originated in exon 5 of the
IE-3 gene, was located outside the region targeted by our shRNA and was the major transcript produced at low
m.o.i. Targeting of this exon 5 transcript with a second shRNA resulted in inhibition of virus replication at both low
and high m.o.i.
Conclusions: These studies indicate that IE-3 has a complex transcriptional profile and that shRNA targeting of this
and other viral regulatory genes which produce multiple transcripts may have unexpected effects on virus
replication.
Background
RNAi is widely used to selectively inhibit gene expres-
sion both in vivo and in vitro. The process utilizes small
RNAs to interfere with gene expression at both tran-
scriptional and post-transcriptional levels by targeting
newly transcribed RNAs for nucleolytic attack and also
by causing transcriptional silencing of particular chro-
mosomal regions, such as those rich in heterochromatin.
T h e s eR N A sa r ek n o w na ss i R N A s[ 1 - 3 ] .A n o t h e rc l a s s
of small RNA molecules known as micro RNAs (miR-
NAs) may repress gene expression through inhibition of
protein synthesis due to imperfect base pairing with 3’
untranslated regions of messenger RNAs (mRNAs) [4].
Not surprisingly, RNAi has attracted considerable inter-
est as a possible therapy for various types of virus infec-
tion. Numerous reports have documented the inhibitory
effects of siRNA and miRNA on both RNA and DNA
virus infection in vivo and in vitro.T h e s ei n c l u d eR N A
viruses such as HIV-1 [5-7], hepatitis A, B and C
[8-10]), dengue virus [11] and influenza A virus [12],
poliovirus [13] and DNA viruses such as herpes simplex
virus type 1 [14], human papillomavirus [15], Epstein
Barr virus [16,17] and human cytomegalovirus [18,19]
have also been reported to be susceptible to RNAi.
Using siRNAs clinically, however, poses some challenges
including the development of adequate delivery methods
and the elimination of “off-target” effects. * Correspondence: satherton@georgiahealth.edu
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and also in plants, RNAi functions as an anti-viral
defense mechanism and limits virus replication
[20-22]. Whether RNAi acts in a similar manner in
higher organisms and in mammals is still open to
question [4,23,24]. Not surprisingly, natural selection
has resulted in the evolution of various viral escape
mechanisms which allow virus to circumvent RNAi
and replicate freely. Several plant viruses produce pro-
teins which inhibit host RNAi processes; for example,
the HC-Pro protein of potyviruses inhibits Dicer func-
tion, while the P19 protein of tombusviruses appears
to sequester siRNAs [25,26]. However, in vertebrates,
evidence for virus-induced silencing by RNAi is less
widespread. In cell culture, the B2 protein of Noda-
mura virus has been shown to inhibit host RNAi and
adenovirus VA1 noncoding RNA has been reported to
inhibit siRNA and miRNA production by acting as a
decoy for proteins involved in RNAi [27,28]. Ebola
virus VP35 protein has also been recently reported to
be a suppressor of RNAi [29].
Human cytomegalovirus (HCMV) is a member of the
betaherpesvirus family and is present in a high percen-
tage of the general population. It has a genome of
approximately 230 kb and poses a danger to health in
situations of immune suppression, such as in transplant
recipients and HIV infected patients [30-32]. HIV-
induced immunodeficiency often leads to reactivation of
HCMV, and HCMV infection of the retina may lead to
retinal destruction and subsequent blindness [33].
MCMV is often used as a model for HCMV infection.
The immediate early-3 gene (IE-3) of MCMV is essen-
tial for virus growth and deletion of IE-3 results in no
virus accumulation in MCMV infected NIH3T3 cells at
both low (0.05) and high [2] m.o.i.’s [34]. The gene con-
sists of five exons, with exons 1, 2, 3 and 5 being spliced
together to form the full length IE-3 transcript. Exon 4
i sn o tr e q u i r e df o rI E - 3m R N Ab u ti su s e di n s t e a di n
place of exon 5 to form the IE-1 mRNA. Thus, IE-1 and
IE-3 share the first three exons but differ in their use of
either exon 4 or 5 for the final exon. The expression of
immediate early genes does not require de novo protein
synthesis and they are the earliest genes to be expressed
upon virus entry into cells. Among their functions are
the activation of viral early genes, the interaction with
various host genes and proteins in order to prepare the
cell for virus infection and the repression of their own
synthesis.
Insights into immediate early gene functions have
come mainly from HCMV IE-2, which is the human
equivalent of the murine IE-3 gene. It produces a num-
ber of smaller transcripts, in addition to the full length
transcript, mainly at later times following infection [35].
These transcripts originate predominantly in exon 5. In
particular, there are two smaller proteins of 60 kd and
40 kd which are identical to the C-terminus of HCMV
IE-2 and which are expressed at late times following
infection [36,37]. The smaller IE-2 proteins are not
essential for HCMV replication but do contribute to the
expression of other early and late genes and are required
for the production of normal infectious virus titers.
Therefore, despite their truncated form, they appear to
possess the ability to regulate the expression of other
viral genes.
The aim of these studies was to determine if RNAi is
an effective inhibitor of MCMV replication. HCMV has
previously been reported to be susceptible to siRNA
induced inhibition of virus replication at relatively high
m.o.i.’s, suggesting that its murine homolog may likewise
be susceptible to inhibition [18,19]. Therefore, in an
effort to modulate cytomegalovirus infection, we investi-
gated the relationship between small RNA inhibitors
and MCMV infection. Specifically, we wished to deter-
mine if RNAi inhibited virus replication and whether
virus-specific small RNAs could be used as an anti-virus
treatment. Since the MCMV IE-3 gene plays an impor-
tant role in the orderly expression of early and late viral
genes in infected cells, we selected it as a target for
siRNA mediated inhibition. Using small hairpin RNAs
(shRNAs) to target IE-3, we observed that some IE-3
specific shRNAs unexpectedly stimulated virus replica-
tion at low m.o.i.’s, whereas the same shRNAs inhibited
MCMV replication at high m.o.i.’s. Elucidation of the
transcript profile of IE-3 indicated that a different spec-
trum of IE-3 transcripts is produced at low and high m.
o.i. and may be responsible for this unexpected result.
Methods
Cell Lines and Viruses
For these studies, we used a murine bone marrow stro-
mal cell line (M2-10B4) which is readily transfectable
a n da l s os u p p o r t sv i g o r o u sM C M Vr e p l i c a t i o n .M 2 -
10B4 cells were purchased from American Type Culture
Collection (Manassas, Virginia) and cultured in RPMI
1640 supplemented with 10% fetal calf serum, 10 mM
Hepes, 1 mM sodium pyruvate, 45 gm/liter glucose, and
1.5 gm/liter sodium bicarbonate. Cells were infected
with the Smith strain of MCMV at various m.o.i.’sb y
adding virus to cultured cells in serum free medium for
one hour at 37°C. Viral titers were determined by serial
dilution in 24 well plates using M2-10B4 cells as targets
for 5 days, prior to staining of cell monolayers with 1%
Crystal Violet. Plaques were counted under a binocular
microscope.
shRNAs and plasmids
shRNAs were transcribed from an shRNA expression
cassette (SEC) intracellularly under the control of a
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ducing cDNA into an SEC vector using the Silencer
Express siRNA Expression Cassette Kit (Ambion Inc.,
Austin, Texas). The gene target sequence used for
shRNA-1 construction was as follows:
IE-3-AACATAGATATTGTTACAGCA (MCMV
genomic sequence GenBank Accession No. L06816,
nucleotides 8072-8092) [38]. The shRNA-2 target
sequence was: AAGAAGTGCAGGGAAGATAAG
(nucleotides 8969-8989). An IE-3 negative control SEC
contained the same base composition as the above
sequence but the order of nucleotides was scrambled.
Candidate shRNA sequences were identified using
the Ambion siRNA algorithm. The shRNA-1a target
sequence was AACTACTGCCTCACACAGCGC
(nucleotides 8113- 8133) and the shRNA-2a target
sequence was AAGATCAGAGACATGGTAGAC
(nucleotides 8912-8932).
RT-PCR
Total RNA was extracted from M2-10B4 cells using Tri-
zol (Invitrogen, Carlsbad, California) and 500 ng was
used in RT-PCR reactions performed with the Access
RT-PCR kit (Promega, Madison, Wisconsin). For analy-
sis of IE-3 transcript levels, we used a forward primer
located in exon 3 and a reverse primer located in exon
5 of the IE-3 gene, which produce a product of 216 bp.
Primer sequences were: CAACAAGATCCTCGAGT for-
ward (nucleotides 6033- 6049) and GACATG-
GAGGCCGCTGCTGT reverse (nucleotides 8087- 8104,
MCMV genome sequence, GenBank Accession No.
L06816).
Transfection of cell lines
M2-10B4 cells were grown to 80-90% confluence in 6
well or 24 well tissue culture plates and SEC plasmid
DNA or pcDNA 3.1 expressing IE-3 proteins (2 μg) was
introduced into cells using Metafectene Pro transfection
reagent (Biontex Inc., Martinsried, Germany). Transfec-
tion efficiencies were assessed after 24 or 48 hours using
siRNA which had been fluorescently labeled with FAM
(Ambion) or with GFP expression plasmids (pmaxGFP,
Lonza Cologne, Germany). Fluorescence was detected
using a FACS Calibur flow cytometer.
Northern Blots
Total RNA was harvested from M2-10B4 cells using
Trizol reagent (Invitrogen, Carlsbad, California) and 15
μg/lane was electrophoresed on a denaturing formalde-
hyde gel. RNA was transferred to Hybond-N+ mem-
brane (GE Healthcare, Bucks., UK) using standard
capillary transfer and attached to the membrane by UV
irradiation. Blots were probed with alkaline phosphatase
labeled IE-3 probes and bands were visualized using the
CDP-Star chemifluorescence detection system (GE
Healthcare, Bucks., UK).
Immunoblotting
M2-10B4 cells were removed from tissue culture plates
by scraping, collected by centrifugation (250 × g) and
lysed in protein lysis buffer as described [39]. Protein
lysates (40 μg/lane) were electrophoresed on denaturing
polyacrylamide gels then transferred onto Hybond-P
PVDF membranes (Amersham, Piscataway, New Jersey)
by electroblotting. Blots were blocked with 5% non-fat
dried milk and 1% BSA in TBS + 0.1% Tween 20. A rab-
bit anti-MCMV IE-3 polyclonal antibody was raised
against a C-terminal peptide (ISHHEDESGEYESD) of
the full length IE-3 protein (ProSci, Poway, CA) and
used at a dilution of 1:1000. b-actin was detected using
am o u s ea n t i - b-actin monoclonal antibody (Chemicon,
Temecula, California). HRP-labeled goat anti-rabbit sec-
ondary antibody (BD Biosciences, San Jose, California)
or anti-mouse secondary antibodies (BD Biosciences)
were used at a dilution of 1:2000 to detect bound pri-
mary antibody and chemiluminescence was detected
using an ECL kit (Amersham).
5’ RACE
Total RNA was isolated from M2-10B4 cells which had
been infected with MCMV and 1 μgw a su s e df o r
cDNA synthesis using the 5’-RNA Ligase Mediated-
RACE (RLM-RACE) protocol according to the manufac-
turer’s instructions (Ambion Inc.). Two nested sets of
primers were used simultaneously for cDNA synthesis
to divide the gene into two regions of approximately
1 kb each. These nested sets were located at the 3’ end
of the IE-3 mRNA, immediately prior to the stop codon
(nested set-1) and approximately 1.2 kb upstream
of nested set-1 (nested set-2). Nested set-1: 5’
CTCGCAGTCAGACTCATAC 3’ (external) (nucleotides
9577-9595, Gene Bank Accession No. L06816) and 5’
CAGACTCATCCTCATGATG 3’ (internal)(nucleotides
9554-9572). Nested set-2: 5’ GTTGAGGAGAGGAGGA-
GATCAC 3’ (external) (nucleotides 8333- 8354) and 5’
CTGGGGCTCCTGCTCCTCCTGA 3’ (internal)
(nucleotides 8311-8332).
Cloning and Expression of IE-3 Proteins
For expression of full length IE-3 protein we designed
primers located at the beginning of exon 2, which
included the ATG start codon of the full length IE-3
protein and surrounding Kozak sequence and also at
the 3’ end of the IE-3 mRNA in exon 5 and amplified
IE-3 cDNA using RT-PCR. The full length IE-3 primers
were: 5’ AGAGATGGAGCCCGCCGCACCC 3’
(forward) (nucleotides 5807-5827) and 5’ TCACTCG-
CAGTCAGACTCATACTCC 3’ (reverse) (nucleotides
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exon 5 of the IE-3 gene, the same reverse primer as for
the full length IE-3 was used but the forward primer
located at the beginning of exon 5 was as follows: 5’
GACCCGAGATGAACATAGAT 3’.T o t a lR N Aw a s
isolated from MCMV infected cells and 1 μg was used
for RT-PCR. The RT-PCR products were cloned into
the pcDNA 3.1 TOPO TA mammalian expression vec-
tor (Invitrogen, Carlsbad, CA) and individual clones
were sequenced in order to verify that the sequence of
each was correct.
Results
MCMV replication at high m.o.i. in vitro is inhibited by an
IE-3 specific shRNA
T h eI E - 3g e n eo fM C M Vi se s s e n t i a lf o rv i r u sr e p l i c a -
tion [34] and plays an important role in the orderly
expression of viral early and late genes in infected cells.
In order to confirm that MCMV replication was suscep-
tible to inhibition by small RNA molecules, we designed
a shRNA specific for the IE-3 gene targeted to the
beginning of exon 5 and expressed under the control of
a murine U6 promoter which was incorporated into a
shRNA expression cassette (SEC). This shRNA was
known as shRNA-1 and its position is shown in Figure 1.
Control shRNA contained the same base composition
as IE-3 specific RNAs but the base sequence was
scrambled. This inhibitory RNA is therefore initially
expressed as shRNA but is then processed by the
enzyme Dicer into siRNA which is the active compo-
nent in the RNA induced silencing complex (RISC)
[40]. The transfection efficiency of IE-3 specific fluor-
escently labeled siRNAs or GFP reporter plasmids into
t h em u r i n eb o n em a r r o ws t r o m a lc e l ll i n eM 2 - 1 0 B 4
was 70-80% (not shown).
Following MCMV infection of M2-10B4 cells at an m.
o.i. of 2, IE-3 transcripts were detectable at both 3 and
6 hours p.i. However, in those samples which had been
transfected 24 hours previously with shRNA-1, IE-3
transcripts were greatly reduced at the same time points
(Figure 2a). The decrease in IE-3 transcript levels soon
after MCMV infection was reflected in lower levels of
full length 88 kd IE-3 protein in shRNA-1 expressing
cells at later times during the five day virus growth per-
iod (Figure 2b). Up to 24 hours p.i., IE-3 protein could
not be detected using our antibody. However, after 24
hrs p.i. we observed a decrease in full length IE-3 pro-
tein levels compared to control shRNA expressing cells.
In IE-3 shRNA treated cells, IE-3 protein was detectable
at 48 hrs p.i. but then disappeared. Interestingly, we
observed multiple protein products which reacted with
the IE-3 antibody in MCMV infected cell lysates. In
addition to the full length 88 kd IE-3 protein, there was
a series of smaller proteins of ~60 kd, 45 kd and 30 kd
which appeared with late kinetics (72 hrs) and which
s u r p r i s i n g l y ,w e r em o r es t r o n g l ye x p r e s s e di ns h R N A - 1
treated samples than in control shRNA treated samples.
Consistent with the reduced levels of full length IE-3
protein in IE-3 specific shRNA treated samples, there
was also a significant reduction in the amount of virus
replication in the IE-3 depleted samples compared with
controls at day 4 and 5 p.i. (p < 0.005) (Student’sT -
Test) (Figure 2c). Thus, MCMV replication was sensitive
to IE-3-specific shRNA and its replication could be
inhibited significantly in vitro at high m.o.i.’s.
Since multiple IE-3 proteins were detected with our
IE-3 antibody, we performed Northern blots on RNA
isolated from MCMV infected cells treated with either
shRNA or control shRNA at various times p.i., in order
to determine if multiple transcripts were produced by
Figure 1 Location of transcripts produced from the IE-1/3 gene showing locations of both shRNAs used in the experiments described
in this manuscript. ATG-FL: the start codon of full length IE-3.
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the full length IE-3 transcript which would detect any
transcripts ending at the usual IE-3 transcription termi-
nation site and arising from either alternative transcrip-
tion start sites or alternative splicing within the IE-3
coding sequence. In control shRNA treated cells we
observed IE-3 transcripts of approximately 2.1 kb, 1.9 kb
and 1.3 kb beginning at day 2 p.i. (Figure 2d). None of
these transcripts was detected in shRNA treated cells.
Instead, at day 5 p.i., we observed a large increase in
small RNA species which appeared as a smear on agar-
o s eg e l s .T h ep r o t e i np r o d u c t s ,i fa n y ,o ft h e s es m a l l
RNA species, are currently unknown. Thus, IE-3 pro-
duces multiple transcripts, which presumably include
those responsible for producing the 60 kd, 45 kd and 30
kd IE-3 proteins.
There are multiple transcriptional start sites
within the IE-3 gene
In order to better understand the genesis of the smaller
IE-3 proteins, we performed rapid amplification of 5’
cDNA ends (5’ RACE) using RNA from MCMV infected
cells to identify all the transcripts produced from the
IE-3 gene. Although there is little information about
alternative transcripts arising from the MCMV IE-3
locus, in human cytomegalovirus (HCMV) several tran-
scripts arising from the use of alternative splicing and
alternative start codons have been identified. [36,37].
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Figure 2 MCMV replication is inhibited by IE-3 specific shRNA. a) Semi-quantitative RT-PCR (30 cycles) of total RNA from MCMV infected M2-
10B4 cells at either 3 or 6 hours p.i. Cells were transfected with shRNA-1 or a control shRNA 24 hours prior to MCMV infection. b) Western blot
of proteins expressed in cells infected with MCMV and treated with either shRNA-1 or control shRNA. c) Viral growth curve showing the effect of
shRNA-1 (dotted line), or control shRNA (solid line) on MCMV growth in M2-10B4 cells infected with MCMV at day 0 at an m.o.i. of 2. Results are
typical of three such experiments performed. ** Significantly different from control p < 0.01. (d). Northern blot of total RNA extracted from
MCMV infected M2-10B4 cells at various times p.i. following treatment with either shRNA-2 or control shRNA.
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2 kb in length, we divided the gene into two fragments
of approximately 1 kb each for amplification, with one
primer located at the 3’ end of the transcript immedi-
ately upstream of the TGA stop codon, while the second
primer was located near the 5’ end of exon 5. Using
RNA prepared from both early (24 hrs p.i.) and late
(120 hrs p.i.) times after infection and from high (m.o.i.
= 2) and low (m.o.i. = 0.2) m.o.i.’s, we amplified RNA
from M2-10B4 cells infected with MCMV. At 24 hrs p.
i., there was a marked difference in the cDNA profiles
amplified from m.o.i. = 2 and m.o.i. = 0.2 cells (Figure
3a). In particular, there was a noticeably greater amount
of longer, full length IE-3 transcripts in the m.o.i. = 2
cells compared to the m.o.i. = 0.2 cells. Overall, we
identified four sites of transcription initiation in the IE-3
gene (Figure 1 and Figure 3b). The first was the full
length IE-3 transcript initiation site at the beginning of
exon 1. This transcript was detected principally at 24
hrs p.i. in m.o.i. = 2 samples but not in other samples.
A second transcription initiation site was detected at the
beginning of exon 2. The transcript initiated from this
site lacked the noncoding exon 1 and was approximately
300 bp shorter than the full length transcript. It conse-
quently lacked the normal 5’ untranslated region of the
IE-3 full length mRNA. The canonical ATG start codon
of the full length IE-3 protein is contained within this
transcript but it is located just 4 bp into the transcript
making it unlikely that it would be used as a start codon
d u et ot h el a c ko fa5 ’ untranslated region and riboso-
mal binding site. This transcript was particularly com-
mon at m.o.i. = 2 but was also detected at m.o.i. = 0.2.
A third transcript initiation site was detected in exon
5, 164 nucleotides from the 5’ end of the exon
(nucleotide 764 of the IE-3 gene). This transcript is
designated “exon 5-164”. The transcript initiated from
this site was particularly prominent at 24 hrs p.i. at m.o.
i .=0 . 2w h e r ei ta p p e a r e dt ob et h em a j o rt r a n s c r i p t
(Figure 3a). The fourth transcript which we detected
was initiated at the 3’end of exon 5 at nucleotide 1277
of this exon (nucleotide 1879 of the IE-3 gene). This
transcript is designated “exon 5-1277” and is only 258
nucleotides upstream from the canonical TGA stop
codon of the full length IE-3 protein. This transcript
appeared to be the predominant transcript at late times
after infection in both m.o.i.= 2 and m.o.i. = 0.2 samples
and if it terminated at the usual IE-3 transcription ter-
mination site, would produce a RNA species of 424
nucleotides. Both the transcript which begins at exon 2
and the transcript beginning at nucleotide 764 have
TATA box homologs located approximately 25-35
nucleotides upstream from their 5’ends suggesting that
they are in fact bona fide transcripts rather than degra-
dation products of the full length transcript. However,
no TATA homolog could be located upstream of the
transcript which begins at nucleotide 1879.
At an m.o.i. of 0.2, we detected no full length IE-3
mRNA in MCMV infected cells. However, we did detect
each of the other three transcripts mentioned above.
Additionally, in both m.o.i. = 2 and m.o.i. = 0.2 infec-
tions we detected several transcripts which began at
exon 2 but which contained internal deletions involving
most of exon 5 (not shown). These appeared to have
undergone a recombination event, either at the DNA or
RNA level, as they were characterized by 4-6 bp regions
of perfect homology immediately before and after the
deletion. Finally, at later times after infection (120 hrs),
the IE-3 transcript profiles from both the m.o.i. = 2 and
d1 p.i.       d5 p.i.
IE-3 FL
Ex 2 tc
Ex 5-164 tc
Ex 5-1277 tc
a
Transcript         Start site (nucleotide)    Transcript size
Full length                        1               2.2kb
Exon 2             300               1.9kb
Exon 5             764               1.5kb
Exon 5          1,879                    0.48kb
b
1,000bp
750bp
500bp
250bp
Figure 3 Identification of transcripts produced from the MCMV IE-3 gene.a )5 ’RACE was performed on RNA isolated from MCMV infected
M2-10B4 cells at either one or five days p.i. using two nested primer sets. Primer set 1 is located just upstream of the IE-3 stop codon and
primer set 2 is located near the beginning of exon 5. Cells were infected at an m.o.i. of either 2 or 0.2. IE-3 FL: full length IE-3 transcript, Ex 2 tc:
transcript initiated from the beginning of exon 2, Ex 5-164 tc: transcript initiated from nucleotide 164 within exon 5 (nucleotide 764 of IE-3) and
synthesized from primers set 2, Ex 5-1277: transcript initiated from nucleotide 1277 within exon 5 (nucleotide 1879 of IE-3) and synthesized from
primer set 1. Numbers underneath each exon show the nucleotide coordinates for the exon. b) Summary of IE-3 transcripts detected and their
nucleotide location within the full length IE-3 cDNA.
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time, the transcript profile was dominated by the tran-
script originating at nucleotide 1879. No full length IE-3
transcripts were detected at this time after infection.
Thus, a diverse array of transcripts was produced from
the IE-3 gene depending on both the m.o.i. and time
following infection.
At low m.o.i., the effect of IE-3 specific shRNA is target
site dependent
Since our initial experiments with shRNA were per-
formed at an m.o.i. of 2, we investigated if shRNA could
inhibit MCMV replication at a lower m.o.i. such as
might be observed during infection in vivo. However,
our results obtained with 5’R A C Ei n d i c a t e dt h a ta tl e a s t
two transcripts which originate from within the IE-3
gene at m.o.i. = 0.2 would not have been targeted by
shRNA-1. Therefore, we designed a second shRNA
which would target not only the exon 1 and exon 2
transcripts but also the exon 5-164 transcript which
appears to be a major species present at one day p.i. at
m . o . i .=0 . 2 .W ec h o s eas h R N As e q u e n c eb e g i n n i n ga t
nucleotide 909 of exon 5 and cloned it into an SEC
expression vector (shRNA-2) (Figure 1). shRNA-2 inhib-
ited MCMV replication at low m.o.i.’s with one to two
log differences in virus titer at day 5 p.i. (Figure 4a).
We also investigated the effects of shRNA-2 on IE-3
protein levels using Western blots. In contrast to infec-
tion at m.o.i. = 2, no full length IE-3 protein was
observed. Instead, a 45 kd protein was the main form of
IE-3 observed in control shRNA treated cells and levels
of the 45 kd protein were decreased in shRNA-2 treated
samples. Surprisingly however, we once again noted that
some IE-3 proteins were elevated as a result of shRNA
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Figure 4 Effect of shRNAs 1 and 2 on MCMV replication at m.o.i. = 0.2. a) An SEC expressing shRNA-2 was transfected into M2-10B4 cells 24
hrs prior to infection with MCMV at an m.o.i. of 0.2. b) Western blot of IE-3 protein levels in shRNA-2 treated and control shRNA treated samples
Effect of MCMV specific shRNA at low m.o.i.’s in vitro. c) Virus titers at day 5 p.i. in M2-10B4 cultures infected with MCMV at the indicated m.o.i.’s.
Dark bars: 50 nM IE-3 specific shRNA-1, white bars: control shRNA. d) Western blot showing the time course of IE-3 protein expression in MCMV-
infected M2-10B4 cells (m.o.i. = 0.2) following transfection of the IE-3 shRNA-1 expressing plasmid. e) Viral titers at day 5 p.i. in M2-10B4 cultures
infected with MCMV at various m.o.i.’s and treated with either shRNA-1a or shRNA-2a.
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and pronounced increase in the synthesis of several
smaller IE-3 proteins at 72 hrs p.i. in shRNA-2 treated
samples. These included species of 60 kd, 30 kd and 25
kd. Thus, increased synthesis of various smaller IE-3
proteins later in infection following shRNA treatment
was a consistent finding in our experiments.
We also treated cells infected with MCMV at m.o.i.=
0.2 with shRNA-1. As this shRNA lies outside the exon
5-164 transcript, we expected that it would have little to
no effect on MCMV replication, compared to shRNA-2.
However, MCMV replication was actually enhanced by
shRNA-1 treatment. At m.o.i.’s of 0.2, 0.02 and 0.002,
MCMV replication in vitro was increased significantly
by siRNA specific for IE-3 (Figure 4c). To verify that IE-
3 specific siRNA treatment resulted in depletion of IE-3
protein, we performed Western blots on MCMV-
infected cell lysates. As we observed with shRNA-1
treatment, there was no detectable full length IE-3 pre-
sent in cells and a 45 kd protein was the main IE-3 pro-
tein present at early times following infection (Figure
4d). However, in contrast to the results obtained with
shRNA-2, we observed increased levels of the 45 kd pro-
tein in shRNA-1 treated cells. shRNA-1 is located at the
beginning of exon 5 and targets the transcripts begin-
ning in exon 1 and exon 2. Thus it appears as if target-
ing these transcripts for degradation enhances the
production of the 45 kd protein.
The location of shRNAs within the IE-3 gene is there-
fore of importance in determining whether the shRNAs
will be inhibitory or stimulatory to MCMV replication
at low m.o.i.’s. One possible trivial explanation for these
observations is that off-target artifacts could have con-
tributed to some of the results described here. There-
fore, to eliminate this possibility we designed other
shRNAs adjacent to the two exon 5 shRNAs described
so far and tested their effects on MCMV replication.
shRNA-1a targeted a sequence 22 nucleotides 3’ of
shRNA-1 and shRNA-2a targeted a sequence 37 nucleo-
tides 5’ of shRNA-2. In all cases shRNAs located near
the beginning of exon 5 stimulated MCMV replication
at low m.o.i.’s, while those located towards the middle
of the exon inhibited replication (Figure 4e).
The origin of the truncated IE-3 proteins
The IE-3 protein profile at low m.o.i.’s and at later times
p.i. at high m.o.i. is dominated by the smaller IE-3 var-
iants which are translated in the same reading frame as
the full length IE-3 protein as they react with the IE-3
antibody. Therefore, we looked for ATG start codons
within the IE-3 gene which could serve as a possible
translation initiation point for these proteins. We identi-
fied three closely spaced ATG codons in exon 3 which
are potential candidates for the 60 kd protein as well as
two at the beginning of exon 5 (Figure 5a). No other in
frame ATG codons were located nearby, with the next
being in the middle of exon 5 making it unlikely that this
codon is used as an initiation codon.
Of the five candidate start codons, the ATG located in
exon 3 at codon 62 gave the highest probability of being
an authentic start codon when analyzed using neural
network software designed to detect start codons in raw
D N As e q u e n c e s[ 4 1 ] .I nf a c ti tr e t u r n e dah i g h e rp r o b -
ability than the authentic ATG start codon used to initi-
ate full length IE-3 synthesis (0.816 vs 0.674). The ATG
present at codon 79 in exon 3 also returned a positive
score, albeit with a lower probability (0.58). However,
the third in frame ATG in exon 3 (codon 93) was not
earmarked as a likely start codon by the analysis algo-
rithm. Both of the in frame ATG codons located near
the start of exon 5 were also flagged as possible authen-
tic start codons (0.507, 0.588), indicating that there are
four potential translation initiation sites in this region.
With regard to the 45 kd IE-3 protein, the predomi-
nant transcript which we observed at early times p.i. at
low m.o.i. in vitro when this protein is produced, is the
transcript which begins at nucleotide 164 of exon 5.
The first in frame ATG codon within this transcript is
located at nucleotide 684 of exon 5, 520 bp downstream
from the transcription initiation site and it contains a
perfect Kozak sequence (ACCATGG) around the poten-
tial start codon (underlined) (Figure 5b). A protein
translated from this start site and terminating at the
canonical IE-3 stop codon would contain 284 amino
acids and would have an isotopically averaged molecular
weight of 32 kd, absent any post translational modifica-
tions. IE-3 is known to undergo sumoylation on at least
three sites which results in a measured molecular weight
greater than that predicted from amino acid sequence
alone but it is not certain what, if any, modifications
might be present around the COOH terminal end of the
protein. Finally, at late times p.i., we observed that the
main transcript originated from the end of exon 5 at
nucleotide 1277. Also at this time, the small IE-3 pro-
tein variants of approximately 30 kd and 25 kd began to
appear. There is an in frame ATG codon 23 nucleotides
downstream of this mRNA transcription start point but
we do not know if this is used for translation initiation
as 23 bp is close to the minimum size of 5’ untranslated
regions in mammalian systems [42].
Therefore, in order to begin to localize the start
codons for the various IE-3 proteins, we cloned the
cDNA for exons 2, 3 and 5, omitting the non-coding
exon 1 and expressed the cDNA under the control of
the human CMV promoter in the pcDNA 3.1 TOPO
vector. We did likewise with cDNA for exon 5. As can
be seen in Figure 5c, the exon 2-5 cDNA directed the
synthesis of the full length IE-3 protein, as well as both
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cDNA directed the synthesis of only the 60 kd and 45
kd proteins. We did not detect the smaller 30 kd and 25
kd IE-3 species observed following shRNA treatment.
Thus, the translational start site of the 60 kd and 45 kd
proteins would appear to be within exon 5.
In order to verify that our IE-3 antibody was detecting
proteins produced from our IE-3 plasmid construct, we
deleted the IE-3 stop codon and cloned the same IE-3 full
length cDNA into pcDNA 3.1 so that the V5 and His tags
located at the C-terminus of the protein would be trans-
lated. We then transfected this construct into M2-10B4
cells and probed Western blots with an anti-V5 antibody.
As shown in Figure 5c, we observed a similar banding pat-
tern to that observed with the IE-3 antibody, indicating
that our antibody was recognizing IE-3 proteins.
Discussion
Our investigation of the effect of small RNA inhibitors
on MCMV infection indicates that virus replication can
be inhibited by small RNA molecules. However, it has
also revealed some unexpected requirements for shRNA
effectiveness. Firstly, we have described multiple IE-3
transcripts and protein species which are m.o.i. depen-
dent. We have identified four transcription start sites
within the IE-3 gene, including the previously described
site at the beginning of exon 1 [43]. In addition, there is
a second site at the beginning of exon 2 with a further
two start sites in exon 5. shRNA-1 which we used initi-
ally to inhibit MCMV replication at m.o.i. = 2 was
located at the beginning of exon 5 in a region lying out-
side the exon 5-164 transcript which is the main tran-
script present at low m.o.i. Coincidentally, treatment
with this shRNA resulted in enhanced virus titers after
5 days at m.o.i. = 0.2. The enhancing effect of shRNA-1
at m.o.i. = 0.2 remains to be completely explained. How-
ever, as the exon 5-164 transcript escaped targeting by
shRNA-1, this could have facilitated increased transla-
tion of the IE-3 45 kd protein product as a result of
increased access to ribosomes. Also, it is possible that
a AGAGATGGAGCCCGCCGCACCCAGTTGCAACATGATCATGATCGCCGATCAGGCATCCGTCAACGCCCACGGCCG
TCACTTGGATGAGAACCGTGTCTACCCATCAGACAAG-GTGCCAGCTCATGTCGCCAACAAGATCCTCGAGTCTGGA
ACCGAAACCGTCCGCTGTGACCTGACTCTGGAGGACATGTTGGGAGACTATGAGTATGATGATCCCACTGAGGAAG
AGAAGATCCTCATGGACCGCATCGCTGACCACGTGGGGAATGATAACAGCGACATGGCCATCAAGCATGCTGCAG-G
ACCCGAGATGAACATAGATATTGTTACAGCAGCGGCCTCCATGTCAGGT
**
ex 2 ex 3
*
ex 3 ex 5
** Full length IE-3 start codon
* Highest probability ATG codon
b Nucleotide 3353 (exon 5) TGATGATGTAGTTGCTAAGTTACATAAGCCCTCTGAGAGTGAGGCAGATGAGGACTTTATTTT
TCAGCAGCCTCAGGAGGAGGAGTATCAGGAGGAGCAGGAGCCCCCAGGTGATCTCCTCCTFTCCTCAACACTTTGATGA
GAGGAGCCCCAGCAGGTCTTCCTCAGATCATGGTGGGCACAGTGGGGGAAACAGTAGAGATGGACAGTTCTATCTGTCTA
GTGGTTCTGAGGATGAAGATGATGAGGATGATGAGCGGGTAGATAGTGGCTACAGGGGGAGCAGTAGGAGTGAAGACAG
CAGCAGGTACAGGCCACACGGAGGCTCCACTCATCAAGGTCCTCCATTAAATCATCAGGGAGCGGGTCCTCTAGACACCA
CCACAAGAGGAAGGCGGTACCTGAACGCCACCATCCTTTCACACCTCCCTCTGCGAAGAGGTATGCCGCCGCTGCCCC
CAGCAGCAGATATGAGTGTCCTGTGCGTGTGGATTCCTCAGACAGTGATGATGCCCCTACCATGGTACAGAGGGGGACC
c
IE-3 FL (88kd)
60kd
45kd
Exons 2-5 Exon 5 Control (GFP)
Host protein
Anti-V5 Ab
Figure 5 Location of possible alternative start codons within the IE-3 gene. a) Spliced nucleotide sequence of IE-3 exons 2, 3 and the first
part of exon 5 showing in frame start codons (bold) and those identified as having an elevated probability of being actual start codons
(underlined) when analyzed with an algorithm designed to identify possible start codons in raw sequence data. b) Sequence of 5’ untranslated
region and putative start codon (bold) of the exon 5-164 transcript. The underlined region is the Kozak sequence. c) Western blot of protein
lysates prepared from M2-10B4 cells 48 hours following transfection with pcDNA 3.1 expression plasmids containing either exons 2, 3 and 5 or
exon 5 alone, using anti-IE-3 antibody. An anti-V5 antibody was also used to confirm the banding pattern observed with the IE-3 antibody was
specific for the transfected exon 2-5 plasmid (right panel).
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could have given rise to smaller transcripts with cryptic
translation start codons hidden within them, leading to
increased translation of smaller IE-3 proteins. This
could also explain the increased levels of smaller IE-3
proteins observed at m.o.i. = 2 following shRNA-1 treat-
ment. If this were the case, one might expect to see
increased levels of smaller transcripts following shRNA
treatment. Using Northern blots, we have observed
greatly increased levels of small RNA species at day 5 p.
i. following MCMV infection at m.o.i. = 2 (Figure 2d).
These RNA species did not appear as discreet bands but
ran as a smear on agarose gels, which may be consistent
with them being due to degradation of larger transcripts.
On the other hand, these small RNA species appeared
suddenly at day 5 p.i. whereas one might have expected
to see a gradual accumulation if they produced by
degradation of larger IE-3 RNA precursors over the
course of a 5 day infection.
Although little is known about the shorter versions of
the IE-3 protein and their possible role in infection,
HCMV has been reported to produce several forms of
IE-2, its human equivalent, either by alternative splicing
or by the use of alternative start codons within the full
length IE-2 mRNA [38]. Previous results obtained prin-
cipally from studies using HCMV have suggested that
shorter versions of IE-2 play largely peripheral roles in
infection compared to the full length IE-3 protein which
is essential for virus replication. The shorter forms are
expressed mainly at later times after infection where
they are believed to be involved in the transactivation of
late genes and although not essential for HCMV replica-
tion, they are required for achieving normal virus titers
[38]. However, our results suggest that the 45 kd protein
may also play an important role at low m.o.i.’s, as it is
the main species present at m.o.i.= 2. The N-terminal
portion of the full length IE-3 protein which is missing
from the shorter 45 kd form is part of one of two trans-
activation domains in the protein (the other being C ter-
minus) which allows it to transactivate a wide variety of
viral and cellular promoters. Loss of this domain could
result in altered transactivation functions. It is therefore
possible that the 45 kd protein binds to a different set
of viral and/or host promoters leading to an altered
spectrum of viral and/or host gene expression compared
to that produced by the full length 88 kd protein. For
instance, at low m.o.i., when the virus may enter latency,
viral gene expression might be directed more at ensur-
ing cell survival than conscripting the cell’sb a s i cf u n c -
tions to maximize production of infectious virus. The
truncated forms of IE-3 could possibly play a role in
this process of cell stabilization and survival. Alterna-
tively, it is possible that the shorter forms of IE-3 bind
to a subset of the promoters bound by the full length
form of the protein. The C-terminal region of the
HCMV IE-2 protein contains both DNA binding and
TATA box binding protein binding regions.
Nevertheless, our data illustrates that when attempting
to block IE-3 expression with shRNA, target sites should
be chosen with care so as to achieve maximum knock-
down of gene function. This presumably holds true of
any gene which produces multiple transcripts and is
particularly important when targeting shRNAs and siR-
NAs to viral transcripts as viruses are expert at making
efficient utilization of their genetic information through
the use of alternative or overlapping reading frames,
cryptic start sites, alternative splicing and antisense
strand transcripts. The multiple transcripts and proteins
produced from the MCMV IE-3 gene are a good exam-
ple of this genetic complexity which varies depending
on infection conditions. Of the proteins produced by
the MCMV IE-3 gene, we have been able to assign
some of them to specific regions of the gene. The start
codons of both the 60 kd and 45 kd proteins appear to
originate from exon 5, as a cDNA containing exon 5
was sufficient to direct the synthesis of these proteins
after transfection into M2-10B4 cells. Therefore inhibi-
tion of IE-3 expression and function focus on the region
located towards the middle of exon 5.
Conclusions
The MCMV IE-3 gene produces several transcripts and
protein products whose relative abundance varies
according to m.o.i. Inhibition of IE-3 gene expression
and hence MCMV replication, using siRNA or miRNA,
requires targeting of these small RNAs to regions of the
gene which are transcribed at the relevant m.o.i.
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